Buparlisib, also known as BKM120; NVP-BKM-120, is an orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. PI3K inhibitor BKM120 specifically inhibits class I PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway.
Related Products:
Idelalisib; Almorexant HCL; IC-87114; Pictilisib; Pictilisib mesylate; XL147; PIK-90; Omipalisib; TG100-115; A66; AS-252424; GSK2636771; CH5132799; 3-methyladenine; AS-604850